Researchers at Johns Hopkins validated an AI-powered blood test that accurately detects liver cancer in diverse populations, using the DELFI platform to analyze cell-free DNA fragments.
RNA-based testing improves detection of MET exon 14 skipping in NSCLC, identifying mutations missed by DNA-only assays, according to new research. Findings may impact eligibility for targeted therapies.
As Cyclospora infections surge in the US, laboratories face increased pressure to quickly differentiate cases, with the CDC reporting 1,947 confirmed infections and 98 hospitalizations across nine states as of July 24.
The company says its US business combines automated kit manufacturing, fulfillment, sample logistics, and digital workflow technology into a single diagnostic testing platform.
The research-use-only platform combines imaging, software, and multiplex protein analysis into a standard 96-well workflow designed to simplify biomarker research.
Siemens Healthineers has added CE-marked capillary blood testing for 24 assays to its Atellica core lab analyzers, enabling labs to use finger prick or heel stick samples in place of standard venipuncture.
The assay is designed to detect minimal residual disease with greater sensitivity than conventional flow cytometry.
Sysmex America will showcase the XR-Series hematology platform and CentralOps informatics solution at ADLM 2026, highlighting advancements for high-volume clinical labs in hematology, hemostasis, and data integration.
ALZpath and Alamar Biosciences have expanded their partnership, granting Alamar commercial rights to use ALZpath’s pTau217 antibody in clinical blood tests for Alzheimer’s disease.
The company is showcasing newly cleared tests and platforms for multiple myeloma, lung cancer, connective tissue disease, and other laboratory applications.
The Fleming Initiative and Cepheid have launched a 30-month study in England to compare rapid molecular and traditional culture screening for drug-resistant carbapenemase-producing Enterobacterales in hospital settings.
Labcorp has announced the upcoming launch of the Marker by Labcorp Genetic Health Panel, which will analyze 163 genes linked to over 100 medically actionable conditions, with results supported by licensed genetic counselors.
The cobas liat system delivers PCR results in 15 minutes, detecting and differentiating between three Bordetella pathogens including whooping cough.
The automated urinalysis system integrates chemistry and microscopy to help labs manage higher testing volumes and reduce manual reviews to under 3%, according to the company.